InspireMD (NYSE:NSPR) Director Buys $76,126.16 in Stock

Posted by Brenda Bartman on May 12th, 2026

InspireMD, Inc. (NYSE:NSPR – Get Free Report) Director Paul Stuka bought 65,626 shares of the business’s stock in a transaction on Friday, May 8th. The shares were acquired at an average price of $1.16 per share, for a total transaction of $76,126.16. Following the completion of the transaction, the director owned 622,871 shares in the company, valued at approximately $722,530.36. This trade represents a 11.78% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Paul Stuka also recently made the following trade(s):

On Monday, May 11th, Paul Stuka bought 10,000 shares of InspireMD stock. The shares were acquired at an average price of $1.19 per share, for a total transaction of $11,900.00.
On Thursday, May 7th, Paul Stuka purchased 6,378 shares of InspireMD stock. The stock was purchased at an average price of $1.15 per share, for a total transaction of $7,334.70.
On Wednesday, May 6th, Paul Stuka purchased 1,517 shares of InspireMD stock. The stock was purchased at an average price of $1.12 per share, for a total transaction of $1,699.04.

InspireMD Trading Down 4.0%

Shares of NYSE:NSPR traded down $0.05 during mid-day trading on Tuesday, reaching $1.20. The stock had a trading volume of 160,686 shares, compared to its average volume of 180,397. The firm has a market cap of $56.27 million, a PE ratio of -1.60 and a beta of 0.82. The firm has a 50 day simple moving average of $1.47 and a two-hundred day simple moving average of $1.73. InspireMD, Inc. has a twelve month low of $1.02 and a twelve month high of $2.93.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Maxim Group assumed coverage on shares of InspireMD in a report on Monday, February 2nd. They set a “buy” rating and a $6.00 target price on the stock. Lake Street Capital set a $4.00 target price on shares of InspireMD in a report on Monday, May 4th. Loop Capital set a $5.00 target price on shares of InspireMD in a report on Tuesday, February 24th. Finally, Piper Sandler restated an “overweight” rating and set a $3.00 target price (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $4.50.

Get Our Latest Analysis on InspireMD

Institutional Investors Weigh In On InspireMD

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ghisallo Capital Management LLC acquired a new stake in InspireMD in the 3rd quarter valued at $2,221,000. Aberdeen Group plc bought a new position in InspireMD during the third quarter worth $5,979,000. Rosalind Advisors Inc. boosted its position in InspireMD by 70.6% during the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after purchasing an additional 1,616,644 shares during the period. Ingalls & Snyder LLC bought a new stake in shares of InspireMD in the third quarter valued at about $542,000. Finally, Virtu Financial LLC bought a new position in shares of InspireMD in the fourth quarter worth about $31,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Company Profile

(Get Free Report)

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.